GlassScriptPhysician profile
Sohail H Khan
NPI 1962594838
$8,693.32
in general payments reported to CMS, 2019-2025
35 companies · $1,436 in 2025
The $1,436 reported for 2025 was more than what 85% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $785 · 2020: $306 · 2021: $759 · 2022: $1,450 · 2023: $1,826 · 2024: $2,132 · 2025: $1,436.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,260 · Education: $134.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,259.55 |
| Education | $134.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,690.93 | 2019-2025 | Farxiga, Lokelma |
| Bayer Healthcare Pharmaceuticals INC. | $1,281.45 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $627.11 | 2019-2024 | Jynarque |
| Horizon Therapeutics Plc | $486.36 | 2019-2023 | Krystexxa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $425.93 | 2023-2025 | Jardiance |
| Opko Pharmaceuticals, LLC | $367.01 | 2019-2025 | Rayaldee |
| Travere Therapeutics, INC. | $328.61 | 2022-2025 | Filspari |
| Novartis Pharmaceuticals Corporation | $295.53 | 2022-2025 | |
| Aurinia Pharma U.S., INC. | $291.76 | 2021-2025 | Lupkynis |
| Mallinckrodt Hospital Products INC. | $291.49 | 2021-2025 | Acthar, Terlivaz |
| Daiichi Sankyo INC. | $275.55 | 2019-2023 | Injectafer |
| Lilly USA, LLC | $242.76 | 2023-2025 | Jardiance |
| Akebia Therapeutics INC | $239.08 | 2019-2024 | Vafseo, Auryxia |
| Ardelyx, INC. | $192.24 | 2024-2025 | Ibsrela |
| Amgen INC. | $185.86 | 2019-2022 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Renalytix Ai, INC. | $183.24 | 2022-2025 | Kidneyintelx Blood Collection Convenience Kit |
| Mallinckrodt Enterprises LLC | $151.48 | 2019 | |
| Calliditas Therapeutics US INC. | $150.48 | 2022-2025 | Tarpeyo |
| Glaxosmithkline, LLC. | $139.55 | 2022-2025 | Benlysta |
| Fresenius USA Marketing, INC. | $135.06 | 2019-2024 | Velphoro |
| Novo Nordisk INC | $129.27 | 2024-2025 | Ozempic |
| Shockwave Medical, INC | $122.19 | 2023 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Scpharmaceuticals INC. | $92.67 | 2025 | |
| Vifor Pharma, INC. | $89.28 | 2019-2022 | |
| Pharmacosmos Therapeutics INC. | $55.19 | 2024 | Monoferric |
| Baxter Healthcare | $46.71 | 2019-2023 | Renal - Pd |
| Alexion Pharmaceuticals, INC. | $33.52 | 2019-2021 | |
| Ultragenyx Pharmaceutical INC. | $25.40 | 2019-2020 | |
| Bard Peripheral Vascular, INC. | $20.73 | 2021 | |
| Alnylam Pharmaceuticals INC. | $19.85 | 2024 | Givlaari |
| Takeda Pharmaceuticals U.S.A., INC. | $19.72 | 2020 | |
| Antares Pharma, INC. | $17.38 | 2022 | |
| Shield Therapeutics INC | $15.45 | 2023 | Accrufer |
| Biomerieux INC | $12.74 | 2019 | |
| Arbor Pharmaceuticals, INC. | $11.74 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sohail Khan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.